As one of the largest pharma companies out there, I suppose it stands to reason that Roche (OTCQX:RHHBY)
would have an above-average level of newsflow, but tracking the
developments at Roche over the last couple of months has been like
trying to sip from a firehose. It’s well worth trying, though, as these
developments have been quite positive and only enhance the long-term
value proposition of Roche shares.
Read more here:
Approval Of The Spark Deal Only Part Of An Expanding R&D-Driven Opportunity At Roche
No comments:
Post a Comment